NBT Bank N.A. Makes New Investment in Novo Nordisk A/S $NVO

NBT Bank N.A. acquired a new stake in Novo Nordisk A/S (NYSE:NVO) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 21,400 shares of the company’s stock, valued at approximately $811,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Novo Nordisk A/S by 2,414.4% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 297,881 shares of the company’s stock worth $14,280,000 after buying an additional 286,034 shares during the period. Trust Co. of Vermont acquired a new position in Novo Nordisk A/S in the second quarter valued at $1,250,000. Pine Valley Investments Ltd Liability Co acquired a new position in Novo Nordisk A/S in the second quarter valued at $2,324,000. Myriad Asset Management Advisors LLC purchased a new stake in Novo Nordisk A/S during the second quarter valued at about $1,846,000. Finally, Tevis Investment Management grew its position in Novo Nordisk A/S by 65.7% during the first quarter. Tevis Investment Management now owns 74,090 shares of the company’s stock valued at $2,813,000 after acquiring an additional 29,390 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 1.0%

NYSE:NVO opened at $39.05 on Friday. The firm has a market capitalization of $174.34 billion, a PE ratio of 9.55, a price-to-earnings-growth ratio of 1.34 and a beta of 0.76. The business’s 50-day moving average is $41.92 and its two-hundred day moving average is $43.99. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.66. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $64.16.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The business had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. Research analysts predict that Novo Nordisk A/S will post 3.42 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were issued a dividend of $0.5786 per share. The ex-dividend date of this dividend was Monday, August 17th. This represents a yield of 258.0%. This is a drop from Novo Nordisk A/S’s previous dividend of $1.2751. Novo Nordisk A/S’s dividend payout ratio (DPR) is 20.05%.

Analyst Upgrades and Downgrades

Several brokerages have commented on NVO. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Novo Nordisk A/S in a research note on Tuesday, September 29th. Jefferies Financial Group reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Weiss Ratings cut Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, October 8th. Cfra downgraded shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 target price for the company. in a research report on Tuesday, September 22nd. Finally, Barclays restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 7th. Five investment analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $59.44.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Awiqli as the first and only once-weekly insulin for children aged 10 and older with Type 2 diabetes. The approval expands Novo Nordisk’s insulin offering and could support long-term sales growth. FDA approves Awiqli for children
• Positive Sentiment: Novo Nordisk is expanding its use of OpenAI’s Rosalind platform for drug discovery, including target identification, molecule design and clinical-trial analytics. Stronger AI capabilities could improve research productivity and support the company’s future pipeline, although financial benefits are likely longer term. Novo Nordisk expands AI drug discovery
• Neutral Sentiment: The company scheduled its next earnings release for November 3. The report will be an important near-term catalyst as investors assess demand, guidance, competitive pressure and the outlook for its GLP-1 portfolio. Novo Nordisk sets November 3 results date
• Neutral Sentiment: Pipeline coverage highlights three regulatory tracks and the upcoming earnings date, keeping attention focused on approval opportunities and clinical progress. These developments could improve sentiment, but their impact depends on regulatory outcomes and data quality. Novo Nordisk pipeline scorecard
• Negative Sentiment: Analysts continue to compare Novo Nordisk unfavorably with Viking Therapeutics, arguing that Viking’s obesity-drug pipeline may offer greater upside. The comparison reinforces concerns that Novo Nordisk faces increasing competition despite its scale and established products. NVO versus VKTX obesity-stock comparison
• Negative Sentiment: Recent commentary points to mixed CagriSema subgroup data and worries about the U.S. market, including competition from Eli Lilly. These issues offset the support from Novo Nordisk’s share buyback program and remain key risks for valuation. Novo Nordisk buyback and CagriSema update

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.